Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Readying Xolair Biosimilar Challenge

Executive Summary

Glenmark has received US FDA clearance of an IND to start clinical studies with a proposed biosimilar version of Xolair. The Indian company appears confident of addressing any price-related challenges although the targeted launch is still some years away.

You may also be interested in...



Sorrento Taps China’s Mabtech For Biosimilars Deal

Sorrento Therapeutics has gained exclusive licensing rights from China’s Mabtech to develop four biosimilar and biobetter products for oncology and auto-immune diseases in western markets and Japan. China’s homegrown biopharmaceutical company has shown another example of its research capability to develop new drugs for the global market.

Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit

Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.

Sun Loses Shine Amid Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel